Download PDF
Thromb Haemost 1996; 76(04): 514-517
DOI: 10.1055/s-0038-1650614
Original Article
Schattauer GmbH Stuttgart

Factor V Leiden, Antiphospholipid Antibodies and Thrombosis in Systemic Lupus Erythematosus

R Fijnheer
Department of Hematology, section Rheumatology and Clinical Immunology, University Hospital Utrecht, The Netherlands
,
D A Horbach
Department of Hematology, section Rheumatology and Clinical Immunology, University Hospital Utrecht, The Netherlands
,
R C J M Donders
1   The Department of Neurology, section Rheumatology and Clinical Immunology, University Hospital Utrecht, The Netherlands
,
H Vilé
Department of Hematology, section Rheumatology and Clinical Immunology, University Hospital Utrecht, The Netherlands
,
E v Oort
Department of Hematology, section Rheumatology and Clinical Immunology, University Hospital Utrecht, The Netherlands
,
H K Nieuwenhuis
Department of Hematology, section Rheumatology and Clinical Immunology, University Hospital Utrecht, The Netherlands
,
F H J Gmelig-Meijling
2   Department of Immunology section Rheumatology and Clinical Immunology, University Hospital Utrecht, The Netherlands
,
Ph G de Groot
Department of Hematology, section Rheumatology and Clinical Immunology, University Hospital Utrecht, The Netherlands
,
R H W M Derksen
3   Department of Internal Medicine section Rheumatology and Clinical Immunology, University Hospital Utrecht, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 09 February 1996

Accepted after resubmission 18 June 1996

Publication Date:
26 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Thromboembolic complications are frequently observed in patients with systemic lupus erythematosus (SLE). Significant associations have been reported between these complications and the presence of antiphospholipid antibodies, notably the lupus anticoagulant and anti-cardiolipin antibodies. Factor V Leiden is a genetic disorder associated with an increased risk of venous thrombosis. We studied these factors in 173 patients with SLE in relation to both arterial and venous thrombosis. The frequency of factor V Leiden in SLE patients is comparable to that in the Dutch population (5%) and a risk factor for venous thrombosis (odds ratio 4.9; Cl 1.2-19.6), but not for arterial thrombosis. The lupus anticoagulant is a risk factor for both arterial thrombosis (odds ratio 7.1; Cl 2.9-17.4) and venous thrombosis (odds ratio 6.4; Cl 2.7-15.4). From multivariate analysis, both the lupus anticoagulant and factor V Leiden appeared independent risk factors for venous thrombosis.

 

  • References

  • 1 Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-698
    PubMedGoogle Scholar
  • 2 Hughes GVR. The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341-344
    CrossrefPubMedGoogle Scholar
  • 3 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522
    CrossrefPubMedGoogle Scholar
  • 4 Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-1506
    CrossrefPubMedGoogle Scholar
  • 5 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
    CrossrefPubMedGoogle Scholar
  • 6 Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, Mertens K, van Mourik JA. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet 1994; 343: 1535-1536
    CrossrefPubMedGoogle Scholar
  • 7 Bertina RM, Koeleman BP, Koster T, Roosendaal FR, Dirven RJ, de Rorde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
    CrossrefPubMedGoogle Scholar
  • 8 Greengard JS, Sun X, Xu X, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va [letter]. Lancet 1994; 343: 1361-1362
    PubMedGoogle Scholar
  • 9 Rosendaal FR, Bertina RM, Reitsma PH. Evaluation of activated protein C resistance in stored plasma. Lancet 1994; 343: 1289-1290
    PubMedGoogle Scholar
  • 10 Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield HF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheumatism 1982; 25: 1271-1275
    CrossrefPubMedGoogle Scholar
  • 11 Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640
    PubMedGoogle Scholar
  • 12 Amout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 1994; 87: 94-99
    CrossrefPubMedGoogle Scholar
  • 13 Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost 1991; 65: 320-322
    PubMedGoogle Scholar
  • 14 Derksen RH, Hasselaar P, Blokzijl L, Gmelig MeylingFH, de Groot PG. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis 1988; 47: 364-371
    CrossrefPubMedGoogle Scholar
  • 15 Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-917
    CrossrefPubMedGoogle Scholar
  • 16 Dizon-Townson D, Hutchison C, Silver R, Branch DW, Ward K. The factor V Leiden mutation which predisposes to thrombosis is not common in patients witth antiphospholipid syndrome. Thromb Haemost 1995; 74: 1029-1031
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Davies K, Ireland H, Athanassiou P, Loizou S, Lane D, Walport MJ. Factor V Leiden mutation and venous thrombosis (letter). Lancet 1995; 345: 132-133
    PubMedGoogle Scholar
  • 18 Reber G, Arvieux J, Comby E, Degenne D, Moerloose de P, Sanmarco M, Potron G. Multicenter Evaluation of Nine Commercial Kits for the Quantitation of Anticardiolipin Antibodies. Thromb Haemost 1995; 73: 444-452
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Triplett DA. Laboratory Diagnosis of Lupus Anticoagulans. Semin Thromb Hemost 1990; 16: 182-192
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Ginsberg JS, Wells PS, Brill EdwardsP, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691
    PubMedGoogle Scholar
  • 21 Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K, Palosuo T. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23-27
    CrossrefPubMedGoogle Scholar
  • 22 Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, Stampfer M. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992; 117: 997-1002
    CrossrefPubMedGoogle Scholar